Regulatory
Orphan Drug Designation
A designation for drugs treating rare diseases (affecting <200,000 people in US). Provides tax credits, fee waivers, and 7 years of market exclusivity upon approval.
See How Orphan Drug Designation Affects Deal Economics
Model deal terms with real benchmark data from 3,000+ biopharma transactions.